ABIONYX Pharma SA (FR:ABNX)
:ABNX
Want to see FR:ABNX full AI Analyst Report?
ABNX Stock Chart & Stats
€3.70
>-€0.01(-0.63%)
At close: 4:00 PM EST
€3.70
>-€0.01(-0.63%)
Day’s Range― - ―
52-Week Range€1.15 - €5.29
Previous CloseN/A
Volume9.43K
Average Volume (3M)284.77K
Market Cap
€126.82M
Enterprise Value€127.21M
Total Cash (Recent Filing)€3.52M
Total Debt (Recent Filing)€3.81M
Price to Earnings (P/E)―
Beta-0.49
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding35,511,654
10 Day Avg. Volume172,880
30 Day Avg. Volume284,772
Financial Highlights & Ratios
PEG Ratio-1.05
Price to Book (P/B)31.58
Price to Sales (P/S)33.12
P/FCF Ratio-42.38
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.47
Revenue Forecast (FY)€4.66M
Bulls Say, Bears Say
Bulls Say
Positive Equity PositionReporting positive equity (~€4.26m in 2025) provides an immediate solvency buffer that supports ongoing R&D and clinical activities. This solvency reduces short-term failure risk and gives management time to pursue financing or partnership options to bridge to value-driving milestones.
Improving Operating Cash BurnA reduction in operating cash outflows versus the prior year signals improving operational control or phasing of spend. If sustained, lower burn increases runway and reduces near-term financing pressure, enabling the company to advance clinical programs with fewer disruptive capital raises.
Revenue Above Near-zero BaseRevenue rising from near-zero levels indicates some commercial or partnership traction and validation of the platform. Durable, continuing revenue growth would support scaling and reduce dependency on financing, making the business model more resilient over a multi-month horizon.
Bears Say
Persistent Negative Cash FlowSustained negative operating and free cash flows imply ongoing funding needs; absent a material change in revenues or costs, the company will require external capital. Repeated financing events risk dilution or higher-cost debt, increasing long-term shareholder dilution and execution risk.
Rising LeverageA near doubling of debt-to-equity over one year reduces financial flexibility and raises fixed obligations. Higher leverage limits options for opportunistic partnerships or R&D spending and increases vulnerability to interest or covenant stress if operating performance does not improve.
Deteriorating Profit MarginsSharp margin deterioration and deeply negative EBIT margin indicate the business currently lacks scalable unit economics. This suggests structural cost intensity or pricing limits that make transitioning to sustainable profitability challenging without major commercial or cost-structure changes.
ABNX FAQ
What was ABIONYX Pharma SA’s price range in the past 12 months?
ABIONYX Pharma SA lowest stock price was €1.15 and its highest was €5.29 in the past 12 months.
What is ABIONYX Pharma SA’s market cap?
ABIONYX Pharma SA’s market cap is €126.82M.
When is ABIONYX Pharma SA’s upcoming earnings report date?
ABIONYX Pharma SA’s upcoming earnings report date is Sep 24, 2026 which is in 149 days.
How were ABIONYX Pharma SA’s earnings last quarter?
ABIONYX Pharma SA released its earnings results on Mar 12, 2026. The company reported -€0.092 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.092.
Is ABIONYX Pharma SA overvalued?
According to Wall Street analysts ABIONYX Pharma SA’s price is currently Overvalued.
Does ABIONYX Pharma SA pay dividends?
ABIONYX Pharma SA does not currently pay dividends.
What is ABIONYX Pharma SA’s EPS estimate?
ABIONYX Pharma SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ABIONYX Pharma SA have?
ABIONYX Pharma SA has 35,511,654 shares outstanding.
What happened to ABIONYX Pharma SA’s price movement after its last earnings report?
ABIONYX Pharma SA reported an EPS of -€0.092 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.448%.
Which hedge fund is a major shareholder of ABIONYX Pharma SA?
Currently, no hedge funds are holding shares in FR:ABNX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
ABIONYX Pharma SA
ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal and ophthalmological diseases. The company is developing CER-001, a negatively-charged lipoprotein particle which contains human recombinant apoA-I, the natural high density lipoprotein (HDL) protein, and sphingomyelin and dipalmitoylphosphatidylglycerol natural phospholipids designed to mimicks the structural and functional biological properties of pre-beta HDL for the treatment of post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients; CER-002, a peroxisome proliferator-activated receptor delta specific agonist for the treatment of cardiovascular and metabolic diseases; and CER-209, a drug candidate for the treatment of metabolic diseases in the liver, as well as atherosclerois and non-alcoholic steato-hepatitis. It has a strategic partnership with GTP Biologics and VBI Therapeutics Group for the bioproduction of the bio-HDL in France. The company was formerly known as Cerenis Therapeutics Holding SA and changed its name to ABIONYX Pharma SA in August 2019. ABIONYX Pharma SA was founded in 2005 and is based in Balma, France.